Abstract

Residual neuromuscular block (RNMB) remains a significant safety concern for patients throughout the perioperative period and is still widely under-recognized by perioperative healthcare professionals. Current literature suggests an association between RNMB and an increased risk of postoperative pulmonary complications, a prolonged length of stay in the post anesthesia care unit (PACU), and decreased patient satisfaction. The 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade provide guidance for the use of quantitative neuromuscular monitoring coupled with neuromuscular reversal to recognize and reduce the incidence of RNMB. Using sugammadex for the reversal of neuromuscular block as well as quantitative neuromuscular monitoring to quantify the degree of neuromuscular block may significantly reduce the risk of RNMB among patients undergoing general anesthesia. Studies are forthcoming to investigate how using neuromuscular blocking agent reversal with quantitative monitoring of the neuromuscular block may further improve perioperative patient safety.

MeSH

Anesthesia, Perioperative Care, Risk, Safety, Neuromuscular Blockade, Neuromuscular Monitoring

Cited by

• Neuromuscular Blocking Agents and Reversal Agents Usage, and Neuromuscular Blockade Monitoring in the Intensive Care Unit - Review Article. Int J Gen Med, 2025
• Sugammadex for Neuromuscular Blockade Reversal: A Narrative Review. J Clin Med, 2025
• Advances in Neuromuscular Monitoring Techniques in Anesthesiology: A 2025 Perspective. Med Sci Monit, 2025
• Analysis of characteristics of patients whose sugammadex claims were denied by the Auto Insurance Claims Review Department of Korean Health Insurance Review & Assessment Service: a retrospective single-center review. Anesth Pain Med (Seoul), 2024
• A Review of Non-Cardiac Complications of General Anesthesia: The Current State of Knowledge. Med Sci Monit, 2025